NCT01554514View on ClinicalTrials.gov

Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

February 14, 2020

Study Completion Date

February 14, 2020

Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
BIOLOGICAL

rituximab

rituximab intravenously 100 mg every week for four doses

Trial Locations (4)

27710

Duke University Medical Center, Durham

30322

Emory University, Atlanta

63110

Washington University, St Louis

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Washington University School of Medicine

OTHER

NCT01554514 - Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura | Biotech Hunter | Biotech Hunter